International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy

International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy

The completion and smooth relocation of the new Hebei Yanda Ludaopei Hospital campus mark a major step forward for the Ludaopei Medical Group’s clinical capacity. On this occasion, internationally renowned hematologist Professor Robert Negrin—Director of the Blood and Marrow Transplantation Program at Stanford University and President-Elect of the American Society of Hematology (ASH)—visited the hospital for an in-depth exchange with Professor Lu Peihua, who leads the Ludaopei Medical Group. Their discussion centered on the evolution of cellular therapies, clinical challenges in CAR-T, and opportunities for global collaboration. Both sides emphasized that cross-border cooperation and open academic exchange are essential engines driving progress in hematologic disease care. Oncology Frontier – Hematology Frontier presents key takeaways from this Sino-U.S. dialogue to offer both practical reference and insight for the cell therapy community.
Professor Daniel Hartson Provides In-depth Analysis of DLBCL’s Genetic Complexity and Innovative Research Models丨EHA 2025

Professor Daniel Hartson Provides In-depth Analysis of DLBCL’s Genetic Complexity and Innovative Research Models丨EHA 2025

In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss cutting-edge topics in basic research and clinical translation in the field of hematolog.Professor Daniel Hartson from the University of Cambridge delivered an insightful presentation on "Deciphering the Genomics of Aggressive Lymphoma." He systematically elaborated on the genetic complexity of Diffuse Large B-cell Lymphoma (DLBCL), shared his team's breakthrough achievements in constructing novel functional genomics models, and emphasized the critical importance of standardized molecular profiling for advancing future clinical research and personalized medicine.
Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025

Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025

In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year's congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the novel trispecific antibody JNJ-79635322 (JNJ-5322) (Abstract: S100) was selected by the congress presidency as one of six "outstanding and practice-changing" pivotal studies for an oral presentation during the plenary session, owing to its breakthrough efficacy. The study showcased the astounding potential of JNJ-5322 in treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).